Vistagen completes PALISADE-4 Phase 3 patient visits; topline data due Q2 2026

Vistagen Therapeutics, Inc.

Last patient completed randomized portion of Phase 3 trial for fasedienol acute treatment of social anxiety disorder.
Topline results for PALISADE-4 expected in second quarter 2026.
FDA has no comments on refined statistical analysis plan incorporating pre-dose SUDS baseline covariate.
Open-label extension remains ongoing; fasedienol has FDA Fast Track designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.